RanReshefMDMSc

PubMed

• Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group.
  Nikolaos Katsivelos, Nikolaos Spyrou, Daniela Weber, Ingrid Vasova, Francis Ayuk
  Transplantation and Cellular Therapy. 2024-11-26
• Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients.
  Carlos A Ortega Rios, Muna Qayed, Aaron M Etra, Ran Reshef, Richard Newcomb
  Transplantation and Cellular Therapy. 2024-11-01
• 1 citations
  Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma.
  Surbhi Sidana, Krina K Patel, Lauren C Peres, Radhika Bansal, Mehmet Hakan Kocoglu
  Blood. 2024-10-04

Journal Articles

• Upper Gastrointestinal Acute Graft-Versus-Host Disease Adds Minimal Prognostic Value in Isolation or with Other Graft-Versus-Host Disease Symptoms as Currently Diagnos...  
  Margaret MacMillan, Sophie Paczesny, Ran Reshef, Daniel Weisdorf, Haematologica

Abstracts/Posters

• The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease
  Ran Reshef, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients...
  Ran Reshef, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Autologous Transplant Recipients Have a Healthier Gut Microbiota at Baseline and Faster Recovery from Microbiome Injury Compared to Allogeneic Transplant Recipients
  Ran Reshef, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Following Solid Organ (SOT) or Allogeneic Hematop...
  Ran Reshef, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Excellent Survival and Immune Reconstitution Following Matched/Mismatched Unrelated and Mismatched Related Transplantation in Adult Patients with Sickle Cell Disease: ...
  Ran Reshef, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019